Pharmacotherapeutic approaches to treating depression during the perimenopause

References

• Maki PM, Kornstein SG, Joffe H, et al. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause. 2018;25:1069–1085.
   PubMed Web of Science ®Google Scholar
• Vivian-Taylor J, Hickey M. Menopause and depression: is there a link? Maturitas. 2014;79:142–146.
   PubMed Web of Science ®Google Scholar
• Natari R, Clavarino AM, McGuire TM, et al. The bidirectional relationship between vasomotor symptoms and depression across the menopausal transition: a systematic review of longitudinal studies. Menopause. 2018;25:109–120.
   PubMed Web of Science ®Google Scholar
• Mitchell BA, Lovegreen LD. The empty nest syndrome in midlife families: a multimethod exploration of parental gender differences and cultural dynamics. J Fam Issues. 2009;30:1651–1670.
   Web of Science ®Google Scholar
• Schmidt PJ, Murphy JH, Haq N, et al. Stressful life events, personal losses, and perimenopause-related depression. Arch Womens Ment Health. 2004;7:19–26.
   PubMedGoogle Scholar
• Epperson CN, Sammel MD, Bale TL, et al. Adverse childhood experiences and risk for first-episode major depression during the menopause transition. J Clin Psychiatry. 2017;78:e298–e307.
   PubMed Web of Science ®Google Scholar
• Wu Z, Fang Y. Comorbidity of depressive and anxiety disorders: challenges in diagnosis and assessment. Shanghai Arch Psychiatry. 2014;26:227–231.
   PubMedGoogle Scholar
• Gordon JL, Peltier A, Grummisch JA, et al. Estradiol fluctuation, sensitivity to stress, and depressive symptoms in the menopause transition: a pilot study. Front Psychol. 2019;10:1319.
   PubMed Web of Science ®Google Scholar
• Gordon JL, Eisenlohr-Moul TA, Rubinow DR, et al. Naturally occurring changes in estradiol concentrations in the menopause transition predict morning cortisol and negative mood in perimenopausal depression. Clin Psychol Sci. 2016;4:919–935.
   PubMed Web of Science ®Google Scholar
• Garay RP, Zarate CA Jr., Charpeaud T, et al. Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Rev Neurother. 2017;17:593–609.
   PubMed Web of Science ®Google Scholar
• Garay RP, Citrome L, Samalin L, et al. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase iii clinical trials of schizophrenia-targeted therapies as found in us and eu clinical trial registries. Expert Opin Pharmacother. 2016;17:921–936.
   PubMed Web of Science ®Google Scholar
• Burt VK, Altshuler LL, Rasgon N. Depressive symptoms in the perimenopause: prevalence, assessment, and guidelines for treatment. Harv Rev Psychiatry. 1998;6:121–132.
   PubMed Web of Science ®Google Scholar
• MacQueen GM, Frey BN, Ismail Z, et al. Canadian network for mood and anxiety treatments (canmat) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations: youth, women, and the elderly. Can J Psychiatry. 2016;61:588–603.
   PubMed Web of Science ®Google Scholar
• APA. Practice guideline for the treatment of patients with major depressive disorder (revision). American psychiatric association. Am J Psychiatry. 2000;157:1–45.
   Web of Science ®Google Scholar
• Kornstein SG, Jiang Q, Reddy S, et al. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2010;71:1088–1096.
   PubMed Web of Science ®Google Scholar
• Clayton AH, Kornstein SG, Dunlop BW, et al. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2013;74:1010–1017.
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
   PubMed Web of Science ®Google Scholar
• Kornstein SG, Clayton A, Bao W, et al. Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. Menopause. 2014;21:799–806.
   PubMed Web of Science ®Google Scholar
• Kornstein SG, Clayton AH, Bao W, et al. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women. J Womens Health (Larchmt). 2015;24:281–290.
   PubMed Web of Science ®Google Scholar
• Zweifel JE, O’Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology. 1997;22:189–212.
   PubMed Web of Science ®Google Scholar
• Rubinow DR, Johnson SL, Schmidt PJ, et al. Efficacy of estradiol in perimenopausal depression: so much promise and so few answers. Depress Anxiety. 2015;32:539–549.
   PubMed Web of Science ®Google Scholar
• Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol. 2000;183:414–420.
   PubMed Web of Science ®Google Scholar
• Soares CN, Almeida OP, Joffe H, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58:529–534.
   PubMed Web of Science ®Google Scholar
• Morgan ML, Cook IA, Rapkin AJ, et al. Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. J Clin Psychiatry. 2005;66:774–780.
   PubMed Web of Science ®Google Scholar
• Gordon JL, Rubinow DR, Eisenlohr-Moul TA, et al. Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial. JAMA Psychiatry. 2018;75:149–157.
   PubMed Web of Science ®Google Scholar
• Schmidt PJ, Ben Dor R, Martinez PE, et al. Effects of estradiol withdrawal on mood in women with past perimenopausal depression: a randomized clinical trial. JAMA Psychiatry. 2015;72:714–726.
   PubMed Web of Science ®Google Scholar
• Goldberg T, Fidler B. Conjugated estrogens/bazedoxifene (duavee): a novel agent for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis. P T. 2015;40:178–182.
   PubMedGoogle Scholar
• Hansdottir H. Raloxifene for older women: a review of the literature. Clin Interv Aging. 2008;3:45–50.
   PubMed Web of Science ®Google Scholar
• Muchmore DB. Raloxifene: a selective estrogen receptor modulator (serm) with multiple target system effects. Oncologist. 2000;5:388–392.
   PubMedGoogle Scholar
• Clifton-Bligh PB, Baber RJ, Fulcher GR, et al. The effect of isoflavones extracted from red clover (rimostil) on lipid and bone metabolism. Menopause. 2001;8:259–265.
   PubMed Web of Science ®Google Scholar
• Tice JA, Ettinger B, Ensrud K, et al. Phytoestrogen supplements for the treatment of hot flashes: the isoflavone clover extract (ice) study: a randomized controlled trial. JAMA. 2003;290:207–214.
   PubMed Web of Science ®Google Scholar
• Formoso G, Perrone E, Maltoni S, et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2016;10:CD008536.
   PubMedGoogle Scholar
• Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359:697–708.
   PubMed Web of Science ®Google Scholar
• Kloosterboer HJ. Tissue-selectivity: the mechanism of action of tibolone. Maturitas. 2004;48(Suppl 1):S30–S40.
   PubMedGoogle Scholar
• Verheul HA, van Iersel ML, Delbressine LP, et al. Selective tissue distribution of tibolone metabolites in mature ovariectomized female cynomolgus monkeys after multiple doses of tibolone. Drug Metab Dispos. 2007;35:1105–1111.
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Petraglia F, Facchinetti F, et al. Effects of org od 14 on pituitary and peripheral beta-endorphin in castrated rats and post-menopausal women. Maturitas. 1987;Suppl 1:35–48.
   PubMedGoogle Scholar
• Tax L, Goorissen EM, Kicovic PM. Clinical profile of org od 14. Maturitas. 1987;Suppl 1:3–13.
   PubMedGoogle Scholar
• Pinto-Almazan R, Segura-Uribe JJ, Farfan-Garcia ED, et al. Effects of tibolone on the central nervous system: clinical and experimental approaches. Biomed Res Int. 2017;2017:8630764.
   PubMed Web of Science ®Google Scholar
• Kulkarni J, Gavrilidis E, Thomas N, et al. Tibolone improves depression in women through the menopause transition: a double-blind randomized controlled trial of adjunctive tibolone. J Affect Disord. 2018;236:88–92.
   PubMed Web of Science ®Google Scholar
• Paterni I, Bertini S, Granchi C, et al. Estrogen receptor ligands: a patent review update. Expert Opin Ther Pat. 2013;23:1247–1271.
   PubMed Web of Science ®Google Scholar
• Nilsson S, Koehler KF, Gustafsson JA. Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov. 2011;10:778–792.
   PubMed Web of Science ®Google Scholar
• Vallee M. Neurosteroids and potential therapeutics: focus on pregnenolone. J Steroid Biochem Mol Biol. 2016;160:78–87.
   PubMed Web of Science ®Google Scholar
• Clayton AH, Ninan PT. Depression or menopause? Presentation and management of major depressive disorder in perimenopausal and postmenopausal women. Prim Care Companion J Clin Psychiatry. 2010;12:PCC 08r00747.
   PubMedGoogle Scholar
• Wariso BA, Guerrieri GM, Thompson K, et al. Depression during the menopause transition: impact on quality of life, social adjustment, and disability. Arch Womens Ment Health. 2017;20:273–282.
   PubMed Web of Science ®Google Scholar
• Gelenberg AJ, Freeman MP, Markowitz JC et al. American psychiatric association. Practice guideline for the treatment of patients with major depressive disorder; 2010. [cited 2019 Jul 07]. Available from: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
   Google Scholar
• Marsh WK, Bromberger JT, Crawford SL, et al. Lifelong estradiol exposure and risk of depressive symptoms during the transition to menopause and postmenopause. Menopause. 2017;24:1351–1359.
   PubMed Web of Science ®Google Scholar
• Hill DA, Crider M, Hill SR. Hormone therapy and other treatments for symptoms of menopause. Am Fam Physician. 2016;94:884–889.
   PubMed Web of Science ®Google Scholar
• Sarri G, Pedder H, Dias S, et al. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the national institute for health and care excellence guideline on menopause. BJOG. 2017;124:1514–1523.
   PubMed Web of Science ®Google Scholar
• Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol. 1977;4:31–47.
   PubMed Web of Science ®Google Scholar
• Bryant C, Judd FK, Hickey M. Anxiety during the menopausal transition: a systematic review. J Affect Disord. 2012;139:141–148.
   PubMed Web of Science ®Google Scholar
• Bromberger JT, Kravitz HM, Chang Y, et al. Does risk for anxiety increase during the menopausal transition? Study of women’s health across the nation. Menopause. 2013;20:488–495.
   PubMed Web of Science ®Google Scholar
• Flores-Ramos M, Silvestri Tomassoni R, Guerrero-Lopez JB, et al. Evaluation of trait and state anxiety levels in a group of peri- and postmenopausal women. Women Health. 2018;58:305–319.
   PubMed Web of Science ®Google Scholar
• Hantsoo L, Epperson CN. Anxiety disorders among women: a female lifespan approach. Focus (Am Psychiatr Publ). 2017;15:162–172.
   PubMedGoogle Scholar
• Khoshbooii R, Hassan SA, Hamzah MSGB, et al. Effectiveness of group cognitive behavioral therapy on depression among iranian women around menopause. J Basic Appl Sci. 2011;55:991–995.
   Google Scholar
• Brandon AR, Minhajuddin A, Thase ME, et al. Impact of reproductive status and age on response of depressed women to cognitive therapy. J Womens Health (Larchmt). 2013;22:58–66.
   PubMed Web of Science ®Google Scholar
• Hofmann SG, Smits JA. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry. 2008;69:621–632.
   PubMed Web of Science ®Google Scholar
• Borges S, Chen YF, Laughren TP, et al. Review of maintenance trials for major depressive disorder: a 25-year perspective from the us food and drug administration. J Clin Psychiatry. 2014;75:205–214.
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Baumann J, Wheeler-Castillo C, et al. The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharmaceuticals (Basel). 2010;3:19–41.
   PubMedGoogle Scholar
• Usall J, Pinto-Meza A, Fernandez A, et al. Suicide ideation across reproductive life cycle of women. Results from a european epidemiological study. J Affect Disord. 2009;116:144–147.
   PubMed Web of Science ®Google Scholar
• Lorenz T, Rullo J, Faubion S. Antidepressant-induced female sexual dysfunction. Mayo Clin Proc. 2016;91:1280–1286.
   PubMed Web of Science ®Google Scholar
• Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000;157:1445–1452.
   PubMed Web of Science ®Google Scholar
• Thase ME, Entsuah R, Cantillon M, et al. Relative antidepressant efficacy of venlafaxine and ssris: sex-age interactions. J Womens Health (Larchmt). 2005;14:609–616.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Filteau MJ, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1–7.
   PubMed Web of Science ®Google Scholar
• Ionescu DF, Rosenbaum JF, Alpert JE. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues Clin Neurosci. 2015;17:111–126.
   PubMed Web of Science ®Google Scholar
• Beral V, Bull D, Doll R, et al. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative group on hormonal factors in breast cancer. Lancet. 1997;350:1047–1059.
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523–534.
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health initiative randomized trials. JAMA. 2013;310:1353–1368.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465–1477.
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ. A “window of opportunity:” the reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent. Brain Res. 2011;1379:244–252.
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409.
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Tuomikoski P, Lyytinen H, et al. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J Clin Endocrinol Metab. 2015;100:4588–4594.
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Tuomikoski P, Lyytinen H, et al. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause. 2015;22:976–983.
   PubMed Web of Science ®Google Scholar
• Wentzensen N, Trabert B. Hormone therapy: short-term relief, long-term consequences. Lancet. 2015;385:1806–1808.
   PubMed Web of Science ®Google Scholar
• Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women’s health initiative randomized trials. JAMA. 2017;318:927–938.
   PubMed Web of Science ®Google Scholar
• NAMS. The 2017 hormone therapy position statement of the north American menopause society. Menopause. 2017;24:728–753.
   PubMed Web of Science ®Google Scholar
• Cobin RH, Goodman NF, Committee ARES. American association of clinical endocrinologists and american college of endocrinology position statement on menopause-2017 update. Endocr Pract. 2017;23:869–880.
   PubMed Web of Science ®Google Scholar
• Grossman DC, Curry SJ, Force USPST, et al.. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US preventive services task force recommendation statement. JAMA. 2017;318:2224–2233.
   PubMed Web of Science ®Google Scholar
• Marjoribanks J, Farquhar C, Roberts H, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017;1:CD004143.
   PubMed Web of Science ®Google Scholar
• Erel CT, Senturk LM, Kaleli S. Tibolone and breast cancer. Postgrad Med J. 2006;82:658–662.
   PubMed Web of Science ®Google Scholar
• Lokkegaard ECL, Morch LS. Tibolone and risk of gynecological hormone sensitive cancer. Int J Cancer. 2018;142:2435–2440.
   PubMed Web of Science ®Google Scholar
• Brambilla DJ, McKinlay SM, Johannes CB. Defining the perimenopause for application in epidemiologic investigations. Am J Epidemiol. 1994;140:1091–1095.
   PubMed Web of Science ®Google Scholar
• Harlow SD, Cain K, Crawford S, et al. Evaluation of four proposed bleeding criteria for the onset of late menopausal transition. J Clin Endocrinol Metab. 2006;91:3432–3438.
   PubMed Web of Science ®Google Scholar
• Phipps AI, Ichikawa L, Bowles EJ, et al. Defining menopausal status in epidemiologic studies: a comparison of multiple approaches and their effects on breast cancer rates. Maturitas. 2010;67:60–66.
   PubMed Web of Science ®Google Scholar
• Willi J, Ehlert U. Assessment of perimenopausal depression: a review. J Affect Disord. 2019;249:216–222.
   PubMed Web of Science ®Google Scholar
• Garay R, Zarate CA Jr., Cavero I, et al. The development of glutamate-based antidepressants is taking longer than expected. Drug Discov Today. 2018;23:1689–1692.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr., Machado-Vieira R. Ketamine: translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders. Mol Psychiatry. 2017;22:324–327.
   PubMed Web of Science ®Google Scholar
• Janssen. Janssen announces u.S. Fda approval of spravato™ (esketamine) ciii nasal spray for adults with treatment-resistant depression (trd) who have cycled through multiple treatments without relief; 2019. [cited 2019 Jul 01]. Available from: https://www.janssen.com/janssen-announces-us-fda-approval-spravato-esketamine-ciii-nasal-spray-adults-treatment-resistant
   Google Scholar
• Li S, Li ZF, Wu Q, et al. A multicenter, randomized, controlled trial of electroacupuncture for perimenopause women with mild-moderate depression. Biomed Res Int. 2018;2018:5351210.
   PubMed Web of Science ®Google Scholar
• Burger HG, Dudley EC, Hopper JL, et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab. 1999;84:4025–4030.
   PubMed Web of Science ®Google Scholar
• Lokuge S, Frey BN, Foster JA, et al. Depression in women: windows of vulnerability and new insights into the link between estrogen and serotonin. J Clin Psychiatry. 2011;72:e1563–e1569.
   PubMedGoogle Scholar
• Rubinow DR, Schmidt PJ. Is there a role for reproductive steroids in the etiology and treatment of affective disorders? Dialogues Clin Neurosci. 2018;20:187–196.
   PubMed Web of Science ®Google Scholar
• Payne JL, Palmer JT, Joffe H. A reproductive subtype of depression: conceptualizing models and moving toward etiology. Harv Rev Psychiatry. 2009;17:72–86.
   PubMed Web of Science ®Google Scholar
• Payne JL. Reproductive psychiatry: giving birth to a new subspecialty. Int Rev Psychiatry. 2019;31:207–209.
   PubMed Web of Science ®Google Scholar
• Soares CN, Zitek B. Reproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability? J Psychiatry Neurosci. 2008;33:331–343.
   PubMed Web of Science ®Google Scholar
• Studd J. Hormone therapy for reproductive depression in women. Post Reprod Health. 2014;20:132–137.
   PubMedGoogle Scholar